Enrolling by invitationPhase 1NCT05983874

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
International AIDS Vaccine Initiative
Principal Investigator
Godelieve de Bree
Amsterdam UMC, location VUmc
Intervention
BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage(biological)
Enrollment
8 enrolled
Eligibility
18-51 years · All sexes
Timeline
2024 – 2025

Study locations (1)

Collaborators

3M · Access to Advanced Health Institute (AAHI) · Polymun Scientific GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05983874 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency →

← Back to all trials